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The Gambian Bone and Muscle Ageing Study is a prospective observational study 
investigating bone and muscle ageing in men and women from a poor, subsistence 
farming community of The Gambia, West Africa. Musculoskeletal diseases, including 
osteoporosis and sarcopenia, form a major part of the current global non-communicable 
disease burden. By 2050, the vast majority of the world’s ageing population will live in 
low- and middle-income countries with an estimated two-fold rise in osteoporotic frac-
ture. The study design was to characterise change in bone and muscle outcomes and 
to identify possible preventative strategies for fracture and sarcopenia in the increasing 
ageing population. Men and women aged ≥40  years from the Kiang West region of 
The Gambia were recruited with stratified sampling by sex and age. Baseline measure-
ments were completed in 488 participants in 2012 who were randomly assigned to 
follow-up between 1.5 and 2 years later. Follow-up measurements were performed on 
465 participants approximately 1.7  years after baseline measurements. The data set 
comprises a wide range of measurements on bone, muscle strength, anthropometry, 
biochemistry, and dietary intake. Questionnaires were used to obtain information on 
health, lifestyle, musculoskeletal pain, and reproductive status. Baseline cross-sectional 
data show preliminary evidence for bone mineral density and muscle loss with age. Men 
had greater negative differences in total body lean mass with age than women following 
adjustments for body size. From peripheral quantitative computed tomography scans, 
greater negative associations between bone outcomes and age at the radius and tibia 
were shown in women than in men. Ultimately, the findings from The Gambian Bone and 
Muscle Ageing Study will contribute to the understanding of musculoskeletal health in a 
transitioning population and better characterise fracture and sarcopenia incidence in The 
Gambia with an aim to the development of preventative strategies against both.
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inTrODUcTiOn
Health priorities in low and middle-income countries (LMICs) 
have until recently focused on infectious diseases. As these popu-
lations undergo social, economic, and environmental transition, 
non-communicable diseases (NCDs) of older age are becoming 
prevalent. As life expectancy is increasing, within 35  years the 
vast majority of the world’s older population will live in LMICs, 
with a consequent increase in associated NCDs (1, 2). The life 
expectancy in 2015 in The Gambia was 59.8 years in men and 
62.5 years in women. In the Kiang West region, it was 65.3 and 
73.5 years, respectively (3). In addition to musculoskeletal dis-
eases, the prevalence of other diseases in adults in The Gambia 
include hypertension (27%), malaria (<2%), HIV, and AIDS 
(1.8%) (3–5). In the current study, musculoskeletal disease is a 
term used to describe osteoporosis (increased risk of fragility 
fracture) and sarcopenia (loss of muscle mass and strength), 
which are major contributors to the global NCD burden (6). For 
example, osteoporotic fracture is expected to double in LMICs by 
2040 (7). The current cohort provides a baseline from which to 
characterise these changes as the population undergoes transition 
and to determine the individual, societal, and economic impact 
of osteoporosis and sarcopenia, and the associated increase in 
falls/fragility fractures, disability, morbidity, and mortality—all 
of which are currently unknown.
The first study to investigate bone health in The Gambia 
was over 30  years ago and used single-photon absorptiometry 
to measure the radius of women aged 18–85 years and showed 
that Gambians had a 5.6% lower bone mineral content (BMC) 
compared to Caucasian women (8); however, this difference was 
attenuated following adjustments for body size. A subsequent 
study in women aged ≥44 years utilised dual photon absorpti-
ometry and showed that BMC at the lumbar spine was 24% lower 
in Gambians compared to Caucasians following adjustments for 
age, weight, and height (9). At that time, the incidence of fra-
gility fractures was reported to be rare, paralleling the current 
low prevalence of osteoporosis throughout sub-Saharan Africa, 
though it is important to note the scarcity of available data 
(10, 11). The very limited data on bone health of Gambian women 
utilised imaging devices that were predecessors of the current 
clinical gold standard, dual energy X-ray absorptiometry (DXA) 
(8). In addition, there are no data in Gambian men. Currently, 
habitual calcium intakes are low, and parathyroid hormone 
levels are elevated while 25-hydroxyvitamin D status is good; low 
calcium and high PTH are risk factors for fracture in high-risk 
populations (12–15). The Gambia is undergoing a transition 
towards Western lifestyles particularly with respect to nutrition 
and physical inactivity, which are likely to contribute to the 
predicted rise in fracture risk.
Dual energy X-ray absorptiometry is used to measure areal 
bone mineral density (aBMD) as a predictor of fracture risk in 
older people from populations at high risk of osteoporosis (16). 
However, the use of DXA is of limited value in different ethnicities 
and at different times of life (13, 17). Newer imaging technologies 
such as peripheral quantitative computed tomography (pQCT) 
are valuable as they can measure volumetric BMD (vBMD), 
cortical, and trabecular compartments separately and provide 
information about the structural and geometrical parameters 
that contribute to bone strength (17). The application of DXA 
combined with pQCT in different ethnic populations is an area of 
growing research that allows better understanding of the underly-
ing determinants of bone strength.
Understanding musculoskeletal health and better character-
ising fracture incidence in The Gambia may help in the devel-
opment of preventative strategies against the predicted rise in 
osteoporotic fracture and sarcopenia. Ultimately, this would 
improve quality of life and reduce consequent morbidity and 
mortality associated with the conditions in the ageing popula-
tion in The Gambia. Therefore, the Gambian Bone and Muscle 
Ageing Study (GamBAS) cohort was established to prospectively 
study mus culoskeletal ageing in rural Gambian men and women. 
The primary aim of the study was to determine change in bone 
mineral density in men and women, the secondary aims were 
to characterise change in muscle, determine fracture and sarco-
penia incidence, and finally to determine the biochemical and 
hormonal predictors of the detected changes in bone and muscle. 
This manuscript presents a general cohort description and find-
ings from the baseline data.
sTUDY OUTline
study Design
Recruitment
In 1974, the Medical Research Council United Kingdom (MRC 
UK) established a permanent field station in Keneba (MRC 
Keneba), which is located in the middle of a 750  km2 district 
in the Lower River Region of Kiang West (Figure 1). Research 
facilities in Kiang West were initially set up to support nutrition 
studies in four core villages which have been part of a demo-
graphic surveillance system since 1950 and were the basis for the 
establishment of the comprehensive demographic surveillance, 
the Kiang West Demographic Surveillance System (KWDSS). 
The KWDSS and health care provision service has expanded 
into the wider Kiang West community (3). The population of 
Kiang West was described in 2015 (3), and residents are mainly 
of Mandinka ethnicity (79.9%) followed by Fula (16.2%), Jola 
(2.4%), and others (1.3%). The GamBAS cohort was recruited 
from 10 villages in Kiang West (Figure 1).
All men and women aged 40 years and over and residing within 
the four core survey villages of Kiang West were identified using 
the KWDSS (Figure 2) (3). Potential participants were initially 
selected from the four core villages (Keneba, Manduar, Jali, and 
Kantong Kunda) to ensure a population representative of those 
who were known to have been born locally. Target group sizes 
were not reached; therefore, individuals from six other villages in 
the area were also recruited (Figure 1). Individuals were ranked 
according to the accuracy of date of birth ascertained from the 
KWDSS, from most to least accurate (that is, exact day, month 
or year), where recruitment priority was given to those with the 
most accurate. After initial village sensitisation and discussion 
with the elders, participants were located and approached by 
fieldworkers who explained the study in the local language and 
invited them to participate.
FigUre 1 | Map of the study area. The Kiang West region is located in the lower region of The Gambia.
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Eligibility Criteria
All eligible participants aged 40  years and over were given a 
verbal explanation of all the elements of the study and completed 
a screening questionnaire. If eligible, participants were given an 
information sheet and asked to sign or thumbprint an informed 
consent form and were enrolled in the study. Recruitment 
commenced in March 2011 and baseline measurements in 488 
individuals were completed over 18 months (Figure 2).
Exclusion Criteria
Pregnant and lactating women were excluded. A woman was con-
sidered non-pregnant, non-lactating if she was at least 3 months 
post lactation and had regular menses. Individuals who were 
deemed too physically frail or incapable, due to existing disability 
or chronic illness to attend MRC Keneba for measurements were 
excluded from participating in the study (Figure  2). This was 
determined by the individual themselves, their spouse/relative 
or compound elder or a member of the fieldwork team. Prior to 
enrolment, participants were confirmed to not already be part 
of an on-going study at MRC Keneba (or elsewhere). The use of 
prescribed or self-medication to control pain (e.g., aspirin, par-
acetamol), indigestion (e.g., magnesium trisilicate, dried baobab 
fruit), chronic diseases of ageing (e.g., diuretics, local medicine), 
or use of chemical contraception (e.g., Depo Provera) was not an 
exclusion criterion.
Follow-up
The first follow-up measurements were scheduled 1.5–2  years 
later (1.7 ± 0.2 years) after the baseline measurement and were 
completed by the end of 2015 (Supplementary Material, Figure 2). 
Of the 488 participants who attended baseline visits, 380 had a 
repeated set of complete measurements taken. The remaining 
108 participants who did not visit Keneba were approached for 
home visit: 85 were measured at home, 9 were away or could not 
be reached, 6 were excluded because they were too frail for the 
home visit, 4 died, and 4 withdrew consent (Figure  2), with a 
dropout rate of 4.7%. In the 85 participants that were measured 
at home, data collected were anthropometry, grip strength, and 
health questionnaires. Further follow-up measurements are being 
scheduled for 2017–2018.
Measurements
Anthropometry and Questionnaires
Sitting and standing height (cm), weight (kg), mid upper arm 
circumference, and four skinfold measurements were measured 
(triceps, biceps, subscapular, and suprailiac). Blood pressure was 
measured using the OMRON 705IT blood pressure monitor dur-
ing sitting, supine, and standing, and systolic and diastolic readings 
were recorded. A musculoskeletal and general health question-
naire collected data on: activities of daily living (e.g., working 
FigUre 2 | Flow diagram of participant recruitment.
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on a farm, gardening, performing five daily prayers, and fetching 
water), mental health, diagnosed illnesses (e.g., tuberculosis, 
diabetes mellitus, and leprosy), medication use, falls, fractures, 
musculoskeletal pain (located on specific body parts), lifestyle 
(occupational activities and domestic work), social demograph-
ics (including marital status, housing, and number of children), 
and medical history (through review of clinic medical records by 
the study physician/nurse). In women, there were also questions 
on menstrual cycle, breast-feeding history, pregnancy, parity, 
and menopausal status. Self-reported information on the use of 
medications and chronic medical conditions were collected.
Blood and Urine Collection
A 20 mL sample of venous blood was drawn from each partici-
pant in the early morning after an overnight fast; both lithium 
heparin and ethylene diamine tetra acetic acid (EDTA) plasma 
samples and an EDTA cell pellet for DNA extraction were stored 
at −80°C. Blood volume and all laboratory processing details 
were recorded on a data collection form. A 2-h fasting urine 
sample was collected, processed, and acidified and non-acidified 
samples were stored at −20°C. The 24-h urine samples were stored 
at −20°C in acidified and non-acidified aliquots; a further spun 
aliquot was stored at −80°C for assessment of microalbuminuria. 
To date, markers of calcium, vitamin D, bone metabolism, and 
kidney function have been measured.
Dietary Assessment
A 2-day prospective weighed dietary assessment was conducted 
in the participant’s home at a time close to the measurement 
day by trained and experienced fieldworkers. This method has 
been used in previous studies of children, adults, and older 
people in Kiang West (18, 19). Briefly, fieldworkers visited 
participant’s homes and recorded and weighed all food and 
drink items the participants consumed (total prepared minus 
amount left) over 48 h. Data were coded and analysed using 
Diets-In, Nutrients-Out programme with Gambian food tables 
(20, 21).
Dual-Energy X-ray Absorptiometry
Each participant was scanned at the whole body, hip, spine, and 
forearm by DXA as previously described (22) (GE Lunar Prodigy, 
Waltham, MA, USA) software version 10; iDXA (GE Lunar 
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Prodigy, Waltham, MA, USA) was introduced during the first 
follow-up and cross calibration data were obtained in 119 adults 
and children at the follow-up measurement. Bone outcomes were 
as follows: areal BMD (aBMD, g/cm2), BMC (g), and bone area 
(BA, cm2). Body composition outcomes were as follows: total 
body fat mass (kg), total body lean mass (kg), and appendicular 
lean mass (kg). Fat and lean mass were also subdivided into the 
following regions: android, which is the lower abdominal area 
of the trunk between the ribs and the pelvis; gynoid, which is 
the region that encapsulates the hips, upper thighs, and but-
tocks. Lateral vertebral assessment (LVA) scans were obtained to 
determine whether there was any spinal degeneration, assessing 
osteoarthritic changes (osteophytes). Vertebral fractures were 
assessed semiautomatically in the GE Lunar software. All scans 
and fractures were assessed by a single reader, trained by an 
expert consultant musculoskeletal radiologist (Figures  3A–C). 
Figure 3A is a representative LVA scan showing no signs of spinal 
degeneration compared to Figures 3B,C. Short-term precision, 
measured as coefficient of variation (CV%) of duplicate measure-
ments in 70 Gambian adults was <1% for all sites for BMD.
Peripheral Quantitative Computed Tomography
Peripheral quantitative computed tomography measurements 
were made at the radius and tibia using a Stratec XCT-2000 scan-
ner (Stratec, Pforzheim, Germany) software version 6.20c, as pre-
viously described (23). Measurements were taken at the following 
sites: 4, 33, and 66% radius; 4, 14, 38, and 66% tibia. Forearm 
length was defined as the distance from the distal edge of the ulna 
styloid process to the olecranon. Leg length was defined as the 
distance from the most proximal edge of the medial malleolus to 
the intercondylar eminence. The scan sites were determined using 
a planar scout view of the distal radius or tibia and the reference 
line placed to bisect the lateral border of the end plate. The follow-
ing outcome measures were taken at the 4% site: trabecular vBMD 
(Trab.vBMD, mg/cm3), total vBMD (Total vBMD, mg/cm3), 
cross-sectional area (CSA, mm2); 14, 33, 38, and 66% site: CSA 
(mm2), cortical vBMD (Ct.vBMD, mg/cm3), cortical BMC (Ct.
BMC, mg/mm), Ct.Area (mm2), Ct.Thickness (mm), medul-
lary area (mm2), stress strain index (SSI, mm3), cross-sectional 
moment of inertia (CSMI, mm4), periosteal circumference (mm), 
endosteal circumference (mm); and 66% site: cross-sectional 
muscle area (CSMA, mm2) and muscle density (mg/cm3). The 
range of CVs of duplicate measurements of bone outcomes in 
62 Gambian adults was 1–4% for the radius and 1–3% for tibia 
measurements. The pQCT scans were also used to identify the 
presence or absence of vascular calcification at the 4, 14, 38, and 
66% sites of the tibia (Figures 3D–G).
Jumping Mechanography
To assess lower limb muscle function, a Leonardo Ground 
Reaction Force Platform (Leonardo software version 4.2; 
Novotec Medical GmbH, Pforzheim, Germany) was used as 
previously described (24–26). Participants were asked to per-
form three tests: a two-leg countermovement jump, a hopping 
test, and a chair rise test. Each measurement assesses different 
aspects of muscle strength, maximum power (jump), maximum 
force (hop), and time-to-stand (chair-rise). If a participant did 
not feel comfortable/confident in performing any or all of the 
jumping tests, they were not excluded from participating in other 
measurements.
Grip Strength
Grip strength was measured using a dynamometer (Jamar Hand 
Dynamometer, IL, USA) (27). The individual was seated in an 
upright position with the arm supported on the armrest of the 
chair with the wrist in a neutral position and the thumb facing 
upwards. Participants were instructed to exert maximal force. For 
each individual, we allowed one practice and then took three test 
measurements. The outcome measured was force (kg).
ethics
Ethics was obtained from the MRC Unit The Gambia Scientific 
Co-ordinating Committee (SCC) and joint Gambian Government/
MRC Unit The Gambia Ethics committee (SCC#1222). All par-
ticipants provided written informed consent. All procedures were 
carried out in accordance with the Declaration of Helsinki (28). If 
any participant had potential health problems identified by field-
workers during recruitment or by the team during the field visit, 
they were advised to visit the clinic at MRC Keneba for follow-up 
and were offered transport. Participants with elevated blood pres-
sure [according to WHO guidelines (29)] were followed up and 
treated as appropriate. Any other abnormalities were discussed 
with the study physician who followed-up appropriately. For 
instance, if musculoskeletal abnormalities were detected on the 
scan, the participant was referred for radiography at MRC Fajara.
Power calculation and analyses
Power calculations for GamBAS were determined to detect 
within individual change in femoral neck aBMD as it has the 
worst precision of all the sites measured with DXA. A sample 
size of 66 would be needed to detect a 1% change per annum over 
a random follow-up interval between 1.5 and 2 years later with a 
precision of 30% in the expected rate of change (described fully 
in Supplementary Material). To detect a 2% change over the same 
time with 30% precision, we would need a sample size of 16, or 
37 for a precision of 20% in the expected rate of change. Thus, a 
minimum of 30 participants per 5-year age band will be sufficient 
to identify rates of change within an individual of 1–2% per annum 
at the hip with confidence. In the other DXA and pQCT regions, 
which can be measured with more precision, smaller rates of 
change will be detectable with this number of participants. These 
rates are similar to or less than those observed in Caucasian popu-
lations during ageing and are biologically plausible and clinically 
relevant in terms of fracture risk (30, 31). Stratified sampling was 
used to ensure equal distribution of participants across each of 
the 5-year age bands, namely: 40–44.99, 45–49.99, 50–54.99, 
55–59.99, 60–64.99, 65–69.99, 70–74.99, 75 years and over; 239 
men and 249 women were recruited. The scheduled follow-up 
measurements at a randomised interval between 1.5 and 2 years 
later for each participant will minimise the likelihood that the 
two measurements take place at exactly the same time of year. The 
exact interval for follow-up was different for each individual and 
assigned randomly at recruitment. This design was chosen since 
it allows us to account for inter-individual variation in patterns of 
FigUre 3 | Representative lateral vertebral assessment scans of (a) normal vertebrae, (B)  biconcavity at the spine, (c) severe compression and wedge fractures; 
representative peripheral quantitative computed tomography scans with white arrows indicating vascular calcification from the (D) 4%, (e) 14%, (F) 38%, and (g) 
66% tibia.
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seasonal change (Supplementary Material). Preliminary analyses 
on the baseline data include linear regression models to determine 
relationships between height, weight, musculoskeletal outcomes, 
and age. Analyses were split by sex due to patterns of age-related 
change in bone and muscle varying by sex. The data presented 
are from the baseline visits so all participants had measure-
ments recorded for the primary and secondary outcomes. Some 
DXA and pQCT scans were excluded where significant motion 
artefact was detected which resulted in some missing data and 
were considered missing in these analyses. The missing data 
TaBle 1 | Lifestyle outcomes in men and women.
Men (n = 239) Women (n = 249)
number of marriages
Never married 6 (3) 8 (3)
Once 217 (91) 120 (48)
Twice 8 (3) 65 (26)
Three or more 2 (1) 56 (22)
Missing data 6 (3) –
living arrangement
Alone 5 (2) 16 (6)
With 1 spouse and no children 4 (2) 3 (1)
With 1 spouse and children 128 (54) –
With co-wives/spouses 3 (1) 134 (54)
With children only 2 (1) 83 (33)
With co-wives/spouses and children 89 (37) –
Others – 12 (5)
Missing data 8 (3) 1 (0)
smoking status
Non-smoker 181 (76) 202 (81)
Current smoker 55 (23) 39 (16)
Missing data 3 (1) 8 (3)
Farm or field work
No 36 (15) 25 (10)
Used to but not anymore 8 (3) 7 (3)
Yes currently 192 (80) 211 (85)
Missing data 3 (1) 6 (2)
Perform five daily prayers
Yes, with difficulty but without help 15 (6) 8 (3)
Yes, without difficulty 220 (92) 232 (93)
Only with help – 1 (0)
Missing data 4 (2) 8 (3)
Musculoskeletal pain
Back pain 94 (39) 128 (51)
Hip pain 92 (39) 121 (49)
Knee pain 95 (40) 126 (51)
Values are frequency (%).
TaBle 2 | Nutritional intake of men and women.
Men (n = 225)a Women (n = 242)a p-value
Calcium (mg/day) 295.9 ± 175.9 378.0 ± 176.0 <0.0001
Phosphorus (mg/day) 620.2 ± 243.4 836.4 ± 275.4 <0.0001
Iron (mg/day) 25.0 ± 16.5 37.2 ± 25.8 <0.0001
Zinc (mg/day) 7.0 ± 2.8 9.3 ± 3.0 <0.0001
Dietary fibres (mg/day) 33.9 ± 12.4 44.4 ± 14.2 <0.0001
Phytate (mg/day) 1.0 ± 0.4 1.3 ± 0.5 <0.0001
Potassium (mg/day) 1,800.1 ± 705.4 2,409.0 ± 868.9 <0.0001
Magnesium (mg/day) 388.4 ± 150.4 527.3 ± 192.9 <0.0001
Values are mean ± SD.
Bold indicates significance.
Dietary intakes were estimated from 2-day weighed diet diaries, and intakes calculated 
from Gambian food tables.
a21 participants did not have dietary information available.
7
Zengin et al. Gambian Bone Muscle Ageing Study
Frontiers in Endocrinology | www.frontiersin.org August 2017 | Volume 8 | Article 219
were independent of the participant’s age and did not affect the 
preliminary analyses but may have reduced statistical power in 
some age bands. The participants who had missing data were not 
excluded from other measurements.
resUlTs: KeY FinDings FrOM 
Baseline MeasUreMenTs
Population characteristics
Kiang West residents are mainly Muslim (3); GamBAS partici-
pants reported that they pray five times a day and most men and 
women were able to perform these prayers without physical 
difficulty (Table 1). Praying five times a day involves standing, 
kneeling, and rising from the floor multiple times. The question-
naire regarding musculoskeletal pain revealed that a higher pro-
portion of women experienced musculoskeletal pain compared 
to men at the: back (51 vs 39%), hip (49 vs 39%), and knees (51 
vs 40%); this may potentially be due to the subsistence fieldwork 
being undertaken primarily by women (Table  1). The villages 
are divided into compounds where extended multigenerational 
families live together. Polygamy is practiced in this population; 
women have one husband at any one time whereas men may 
have up to four wives. Women often live in one hut with their 
co-wives and men often live separately; 99.5% of men and 98.8% 
of women reside in dwellings with corrugate roofs. Women had a 
median of 9 (IQR: 7–10) children that were born alive. The main 
livelihood is rural subsistence farming where income and eating 
patterns depend on available foods that fluctuate throughout the 
year and are greatly influenced by the annual rainy season (June 
to October). This influences intakes of specific foods, nutrients, 
and energy intake. Dietary intakes of key micronutrients remain 
low and relatively unchanged to our previous work. Overall, 
women had higher intakes of all micronutrients. Some notable 
sex differences include a 21% greater daily habitual calcium 
intake in women than in men (Table 2). The greatest sex differ-
ence was seen in daily habitual iron intake, where women had 
a 33% greater daily iron intake compared to men. Across the 
age bands, daily habitual calcium intake [mean (SD)] was 295.9 
(175.9) mg/day in men and 378.0 (176.0) mg/day in women 
(Table 2).
Bone, Body composition, and age
Baseline data describing anthropometry and body composi-
tion in men and women are shown in Tables 3 and 4. In men, 
the most significant negative associations with age were for 
weight (−0.29 kg, p < 0.0001) and total body lean mass (−0.24, 
p < 0.0001). In women, anthropometry and body composition 
outcomes all had significant negative associations with age, with 
the greatest difference observed in weight (−0.26 kg, p < 0.0001). 
Men had greater negative differences in total body lean mass with 
age than women following adjustments for weight and height 
(R2 =  0.90, interaction p <  0.0001). Waist circumference and 
body fat outcomes were not different with age in both men and 
women.
Dual energy X-ray absorptiometry bone parameters in 
men and women are displayed in Tables  5 and 6, respectively. 
Baseline cross-sectional data show preliminary evidence for bone 
and muscle loss with age. In both men and women, there were 
negative associations between age, and DXA bone outcomes 
at all sites, particularly clinically relevant sites including spine, 
total hip, and femoral neck aBMD (Figures 4A–C). There were 
positive associations with BA and age at the total hip and radius 
in both men and women following adjustments (Tables 5 and 6). 
TaBle 3 | Anthropometry and body composition in men.
age (yr) 40–44 (n = 25) 45–49 (n = 34) 50–54 (n = 29) 55–59 (n = 31) 60–64 (n = 27) 65–69 (n = 35) 70–74 (n = 30) 75+ (n = 28) β-coefficient (95% ci) p-value
Weight (kg) 66.9 ± 10.8 61.5 ± 9.5 64.1 ± 12.3 59.1 ± 10.8 59.2 ± 8.4 59.5 ± 9.6 55.8 ± 7.6 53.8 ± 7.5 −0.29 (−0.39, −0.19) <0.0001
Height (cm) 171.2 ± 5.1 171.0 ± 5.9 171.2 ± 6.7 170.3 ± 6.8 169.1 ± 8.7 167.4 ± 7.0 168.7 ± 7.9 164.9 ± 6.0 −0.16 (−0.23, −0.08) <0.0001
Sitting height (cm) 86.2 ± 3.7 85.2 ± 3.1 85.1 ± 4.1 84.0 ± 3.4 83.7 ± 4.0 82.9 ± 3.6 83.1 ± 4.2 81.2 ± 2.7 −0.11 (−0.15, −0.08) <0.0001
Sit:stand height ratio 0.50 ± 0.02 0.50 ± 0.01 0.50 ± 0.01 0.49 ± 0.01 0.50 ± 0.01 0.50 ± 0.01 0.49 ± 0.01 0.49 ± 0.02 −0.0002 (−0.0004, −0.00008) 0.003
BMI 22.8 ± 3.7 21.0 ± 3.0 21.8 ± 3.5 20.3 ± 2.9 20.7 ± 2.8 21.2 ± 3.2 19.6 ± 2.3 19.8 ± 2.5 −0.06 (−0.09, −0.03) <0.0001
Waist circumference (cm) 79.2 ± 8.5 76.5 ± 8.0(n=32) 80.1 ± 8.4 77.8 ± 8.5 77.1 ± 17.1 79.2 ± 9.3 76.1 ± 7.9(n=29) 75.8 ± 8.6 −0.06 (−0.16, 0.04) 0.243
Total body fat mass (kg) 11.0 ± 6.6(n=24) 7.2 ± 5.3 9.7 ± 7.5 7.2 ± 6.0 8.1 ± 5.4 9.3 ± 6.7 7.3 ± 4.6(n=29) 7.1 ± 4.2(n=26) −0.05 (−0.12, 0.01) 0.120
Total% fat 15.5 ± 7.3(n=24) 11.0 ± 6.4 14.1 ± 8.4 11.1 ± 6.9 13.0 ± 7.3 14.6 ± 8.1 12.6 ± 6.6(n=29) 12.7 ± 6.2(n=26) −0.007 (−0.08, 0.08) 0.865
Android fat mass (kg) 0.9 ± 0.7 0.6 ± 0.5 0.8 ± 0.7 0.6 ± 0.6 0.7 ± 0.6 0.8 ± 0.7 0.5 ± 0.4 0.6 ± 0.5(n=26) −0.004 (−0.01, 0.002) 0.203
Gynoid fat mass (kg) 2.2 ± 1.1(n=24) 1.5 ± 1.0 1.9 ± 1.3 1.4 ± 1.0 1.6 ± 0.9 1.8 ± 1.0 1.5 ± 0.9(n=29) 1.4 ± 0.7(n=27) −0.01 (−0.02, 0.0006) 0.051
FMI (kg/m2) 3.8 ± 2.3(n=24) 2.5 ± 1.7 3.3 ± 2.5 2.4 ± 1.9 2.8 ± 2.0 3.3 ± 2.4 2.6 ± 1.6(n=29) 2.6 ± 1.6(n=26) −0.01 (−0.03, 0.01) 0.292
Total body lean mass (kg) 53.2 ± 5.6(n=24) 51.7 ± 5.8 51.5 ± 6.9 49.5 ± 5.9 48.4 ± 5.1  47.6 ± 4.9 45.8 ± 5.5(n=29) 44.1 ± 5.0(n=26) −0.24 (−0.29, −0.18) <0.0001
aLM (kg) 25.6 ± 3.1 24.6 ± 3.5 24.6 ± 3.9 23.2 ± 3.2 22.4 ± 2.6 21.9 ± 2.8 20.9 ± 3.0 20.0 ± 2.9(n=27) −0.1 (−0.2, −0.1) <0.0001
Android lean mass (kg) 3.4 ± 0.5 3.3 ± 0.4 3.3 ± 0.5 3.2 ± 0.4 3.3 ± 0.4 3.2 ± 0.4 3.2 ± 0.5 2.9 ± 0.4(n=26) −0.009 (−0.01, −0.004) <0.0001
Gynoid lean mass (kg) 7.7 ± 1.1(n=24) 7.4 ± 1.1 7.3 ± 1.2 6.9 ± 0.9 6.8 ± 0.9 6.7 ± 0.8 6.5 ± 0.8(n=29) 6.2 ± 0.7(n=27) −0.04 (−0.05, −0.03) <0.0001
aLMI (kg/m2) 8.7 ± 0.9 8.4 ± 1.1 8.4 ± 1.0 8.0 ± 0.8 7.8 ± 0.7 7.8 ± 0.8 7.3 ± 0.8 7.3 ± 0.8(n=27) −0.04 (−0.05, −0.03) <0.0001
Values are mean ± SD.
β-Coefficients are calculated with age as a continuous variable.
Superscript values indicate the group numbers.
Bold indicates significance.
BMI, body mass index; FMI, fat mass index, calculated as whole body fat mass divided by height squared; aLM, appendicular lean mass; aLMI, appendicular lean mass index, calculated as appendicular lean mass divided by height 
squared.
TaBle 4 | Anthropometry and body composition in women.
age (yr) 40–44 (n = 28) 45–49 (n = 32) 50–54 (n = 30) 55–59 (n = 31) 60–64 (n = 31) 65–69 (n = 33) 70–74 (n = 30) 75+ (n = 34) β-coefficient (95% ci) p-value
Weight (kg) 58.1 ± 11.5 60.8 ± 11.4 57.1 ± 10.8 53.8 ± 9.6 53.4 ± 7.2 53.5 ± 9.6 52.2 ± 9.9 49.3 ± 8.5 −0.26 (−0.35, −0.16) <0.0001
Height (cm) 159.3 ± 5.1 159.8 ± 6.1 158.6 ± 6.2 158.1 5.8 157.6 ± 4.9 160.1 ± 5.7 154.8 ± 5.7 154.0 ± 5.7 −0.14 (−0.20, −0.09) <0.0001
Sitting height (cm) 81.7 ± 2.8 81.2 ± 3.5 80.4 ± 2.9 79.1 ± 3.8 79.5 ± 3.1 80.2 ± 3.5 77.8 ± 3.3 76.5 ± 3.3 −0.13 (−0.16, −0.09) <0.0001
Sit:stand height ratio 0.51 ± 0.02 0.51 ± 0.01 0.51 ± 0.02 0.50 ± 0.02 0.50 ± 0.01 0.50 ± 0.02 0.50 ± 0.02 0.50 ± 0.01 −0.0004 (−0.0005, −0.0002) <0.0001
BMI 22.9 ± 4.4 23.9 ± 4.4 22.7 ± 4.3 21.4 ± 3.1 21.4 ± 2.3 20.8 ± 3.2 21.7 ± 3.7 20.7 ± 2.8 −0.07 (−0.10, −0.03) <0.0001
Waist circumference (cm) 70.7 ± 10.1 75.7 ± 9.7 72.0 ± 8.6 70.6 ± 6.6 71.4 ± 6.3(n=29) 71.0 ± 7.1(n=29) 73.3 ± 8.5(n=23) 68.4 ± 5.4(n=19) −0.06 (−0.14, 0.03) 0.203
Total body fat mass (kg) 18.4 ± 8.7(n=27) 20.7 ± 9.3 18.3 ± 8.3 16.3 ± 6.7(n=30) 16.0 ± 4.8 16.1 ± 6.8 16.4 ± 6.7(n=29) 14.1 ± 5.5(n=30) −0.12 (−0.20, −0.05) 0.001
Total% fat 15.5 ± 7.3(n=24) 11.0 ± 6.4 14.1 ± 8.4 11.1 ± 6.9 13.0 ± 7.3 14.6 ± 8.1 12.6 ± 6.6(n=29) 12.7 ± 6.2(n=26) −0.007 (−0.08, 0.08) 0.865
Android fat mass (kg) 0.9 ± 0.7 0.6 ± 0.5 0.8 ± 0.7 0.6 ± 0.6 0.7 ± 0.6 0.8 ± 0.7 0.5 ± 0.4 0.6 ± 0.5(n=26) −0.004 (−0.01, 0.002) 0.203
Gynoid fat mass (kg) 2.2 ± 1.1(n=24) 1.5 ± 1.0 1.9 ± 1.3 1.4 ± 1.0 1.6 ± 0.9 1.8 ± 1.0 1.5 ± 0.9(n=29) 1.4 ± 0.7(n=27) −0.01 (−0.02, 0.0006) 0.051
FMI (kg/m2) 7.2 ± 3.4(n=27) 8.1 ± 3.7 7.3 ± 3.4 6.5 ± 2.6(n=30) 6.4 ± 1.8 6.2 ± 2.5 6.9 ± 2.7(n=29) 6.0 ± 2.2(n=30) −0.04 (−0.07, −0.01) 0.009
Total body lean mass (kg) 36.7 ± 4.1(n=27) 37.0 ± 4.4 35.7 ± 4.0 35.0 ± 4.5(n=30) 34.7 ± 3.6 34.7 ± 3.4 33.4 ± 4.7(n=29) 32.5 ± 4.3(n=30) −0.11 (−0.16, −0.07) <0.0001
aLM (kg) 25.6 ± 3.1 24.6 ± 3.5 24.6 ± 3.9 23.2 ± 3.2 22.4 ± 2.6 21.9 ± 2.8 20.9 ± 3.0 20.0 ± 2.9(n=27) −0.1 (−0.2, −0.1) <0.0001
Android lean mass (kg) 3.4 ± 0.5 3.3 ± 0.4 3.3 ± 0.5 3.2 ± 0.4 3.3 ± 0.4 3.2 ± 0.4 3.2 ± 0.5 2.9 ± 0.4(n=26) −0.009 (−0.01, −0.004) <0.0001
Gynoid lean mass (kg) 7.7 ± 1.1(n=24) 7.4 ± 1.1 7.3 ± 1.2 6.9 ± 0.9 6.8 ± 0.9 6.7 ± 0.8 6.5 ± 0.8(n=29) 6.2 ± 0.7(n=27) −0.04 (−0.05, −0.03) <0.0001
aLMI (kg/m2) 6.6 ± 0.8(n=27) 6.6 ± 0.8 6.4 ± 0.7 6.2 ± 0.6(n=31) 6.2 ± 0.7 5.9 ± 0.6 6.1 ± 0.8 5.9 ± 0.7 −0.02 (−0.03, −0.01) <0.0001
Values are mean ± SD.
β-Coefficients are calculated with age as a continuous variable.
Superscript values indicate the group numbers.
Bold indicates significance.
BMI, body mass index; FMI, fat mass index, calculated as whole body fat mass divided by height squared; aLM, appendicular lean mass; aLMI, appendicular lean mass index, calculated as appendicular lean mass divided by height 
squared.
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TaBle 5 | Dual energy X-ray absorptiometry bone parameters in men.
age (yr) 40–44  
(n = 25)
45–49  
(n = 34)
50–54  
(n = 29)
55–59  
(n = 31)
60–64  
(n = 27)
65–69  
(n = 35)
70–74  
(n = 30)
75+  
(n = 28)
β-coefficient 
(95% ci)
R2 Unadjusted 
p-value
β-coefficient 
(95% ci)
R2 adjusted 
p-value
Whole body
aBMD 
(g/cm2)
1.2 ± 0.1(n=24) 1.2 ± 0.1 1.2 ± 0.1 1.1 ± 0.1 1.1 ± 0.1 1.1 ± 0.1 1.1 ± 0.1(n=29) 1.1 ± 0.1(n=26) −0.003 
(−0.004, 
−0.002)
0.13 <0.0001 −0.002 
(−0.003, 
−0.0008)
0.34 <0.0001
BMC  
(g)
2,804 ± 433(n=24) 2,632 ± 358 2,739 ± 433 2,532 ± 374 2,442 ± 448 2,433 ± 366 2,335 ± 299(n=29) 2,279 ± 380(n=26) −13.3 (−17.4, 
−9.2)
0.15 <0.0001 −3.9 (−6.6, 
−1.1)
0.66 0.007
BA 
(cm2)
2,355 ± 200(n=24) 2,275 ± 212 2,321 ± 233 2,242 ± 217 2,210 ± 243 2,175 ± 215 2,171 ± 204(n=29) 2,087 ± 205(n=26) −6.2 (−8.5, 
−3.9)
0.11 <0.0001 −0.1 (−1.2, 
1.0)
0.83 0.856
spine
aBMD 
(g/cm2)
1.1 ± 0.2(n=24) 1.0 ± 0.1 1.1 ± 0.1 1.0 ± 0.1(n=30) 1.0 ± 0.2 1.0 ± 0.2 1.0 ± 0.2 1.0 ± 0.2(n=26) −0.002 
(−0.004, 
−0.0004)
0.03 0.014 −0.0006 
(−0.002, 
0.001)
0.13 0.486
BMC  
(g)
61.1 ± 12.6(n=24) 57.1 ± 8.9 59.6 ± 11.0 54.5 ± 9.3(n=30) 55.9 ± 17.6 55.4 ± 11.3 54.2 ± 10.8 53.5 ± 13.5(n=26) −0.1 (−0.3, 
−0.02)
0.02 0.025 0.06 (−0.05, 
0.17)
0.31 0.306
BA 
(cm2)
55.7 ± 5.2(n=24) 55.7 ± 4.0 56.4 ± 5.8 54.8 ± 5.2(n=30) 55.9 ± 7.2 54.9 ± 4.8 55.6 ± 6.8 54.6 ± 5.6(n=26) −0.02 (−0.08, 
0.03)
0.003 0.405 0.09 (0.05, 
0.13)
0.56 <0.0001
Total hip
aBMD 
(g/cm2)
1.1 ± 0.2 1.0 ± 0.1 1.1 ± 0.1 1.0 ± 0.1(n=29) 0.9 ± 0.2 1.0 ± 0.1(n=33) 0.9 ± 0.1(n=29) 0.9 ± 0.2(n=27) −0.004 
(−0.006, 
−0.003)
0.14 <0.0001 −0.003 
(−0.005, 
−0.002)
0.20 <0.0001
BMC  
(g)
35.4 ± 6.2 34.2 ± 4.2 35.8 ± 4.5 33.0 ± 4.4(n=29) 31.4 ± 5.9 31.6 ± 4.7(n=33) 31.1 ± 4.4(n=29) 29.7 ± 6.3(n=27) −0.15 (−0.2, 
−0.1)
0.12 <0.0001 −0.07 (−0.1, 
−0.02)
0.32 0.005
BA 
(cm2)
33.3 ± 2.1 33.5 ± 2.6 34.1 ± 2.3 33.4 ± 2.2(n=29) 33.8 ± 2.6 33.0 ± 2.1(n=33) 34.0 ± 2.0(n=29) 33. 0 ± 2.2(n=27) −0.009 (−0.03, 
0.02)
0.002 0.468 0.04 (0.02, 
0.06)
0.52 <0.0001
Femoral neck
aBMD 
(g/cm2)
1.0 ± 0.1 1.0 ± 0.1 1.0 ± 0.1 0.9 ± 0.1(n=30) 0.9 ± 0.1 0.9 ± 0.1 0.8 ± 0.1(n=29) 0.8 ± 0.2(n=27) −0.005 
(−0.007, 
−0.004)
0.22 <0.0001 −0.004 
(−0.006, 
−0.003)
0.31 <0.0001
BMC  
(g)
5.0 ± 1.0 4.7 ± 0.7 5.0 ± 0.7 4.4 ± 0.6(n=30) 4.3 ± 0.8 4.3 ± 0.7 4.0 ± 0.6(n=29) 3.8 ± 0.8(n=27) −0.03 (−0.04, 
−0.02)
0.20 <0.0001 −0.02 (−0.03, 
−0.01)
0.36 <0.0001
BA 
(cm2)
4.8 ± 0.6 5.0 ± 0.6 5.1 ± 0.5 4.8 ± 0.5(n=30) 5.0 ± 0.5 5.0 ± 0.5 4.8 ± 0.4(n=29) 4.8 ± 0.6(n=27) −0.003 
(−0.009, 0.002)
0.01 0.264 0.002 (−0.003, 
0.008)
0.13 0.382
radius
aBMD 
(g/cm2)
0.7 ± 0.1 0.7 ± 0.1 0.7 ± 0.1 0.7 ± 0.1 0.7 ± 0.1 0.7 ± 0.1 0.6 ± 0.1 0.6 ± 0.1(n=27) −0.004 
(−0.005, 
−0.003)
0.25 <0.0001 −0.003 
(−0.004, 
−0.002)
0.34 <0.0001
BMC 
(g)
12.9 ± 1.6 12.2 ± 1.7 12.5 ± 1.9 12.0 ± 1.8 11.4 ± 1.8 11.3 ± 2.1 10.6 ± 1.5 10.2 ± 2.0(n=27) −0.07 (−0.09, 
−0.05)
0.17 <0.0001 −0.03 (−0.05, 
−0.02)
0.49 <0.0001
BA 
(cm2)
17.3 ± 1.6 17.1 ± 2.1 17.5 ± 2.1 17.4 ± 1.8 17.6 ± 2.0 17.3 ± 2.1 17.4 ± 2.0 16.8 ± 1.7(n=27) −0.005 (−0.02, 
0.02)
0.001 0.649 0.03 (0.01, 
0.05)
0.41 0.001
Values are mean ± SD.
Bold indicates significance.
Adjustments were made for weight and height.
β-Coefficients are calculated with age as a continuous variable.
Superscript values indicate the group numbers.
aBMD, areal bone mineral density; BMC, bone mineral content; BA, bone area.
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TaBle 6 | Dual energy X-ray absorptiometry bone parameters in women.
age (yr) 40–44  
(n = 28)
45–49  
(n = 32)
50–54  
(n = 30)
55–59  
(n = 31)
60–64  
(n = 31)
65–69  
(n = 33)
70–74  
(n = 30)
75+  
(n = 34)
β-coefficient  
(95% ci)
R2 Unadjusted 
p-value
β-coefficient  
(95% ci)
R2 adjusted 
p-value
Whole body
aBMD  
(g/cm2)
1.1 ± 0.1(n=27) 1.1 ± 0.1 1.0 ± 0.1 1.0 ± 0.1(n=30) 1.0 ± 0.1 0.9 ± 0.1 0.9 ± 0.1(n=29) 0.9 ± 0.1(n=30) −0.005 (−0.006, 
−0.005)
0.37 <0.0001 −0.004  
(−0.005,  
−0.003)
0.54 <0.0001
BMC  
(g)
2,273 ± 361(n=27) 2,210 ± 366 2,081 ± 449 1,827 ± 300(n=30) 1,752 ± 252 1,749 ± 369 1,679 ± 368(n=29) 1,538 ± 303(n=30) −18.9 (−22.5,  
−15.3)
0.31 <0.0001 −10.6  
(−12.9,  
−8.2)
0.75 <0.0001
BA  
(cm2)
2,025 ± 193(n=27) 2,041 ± 229 1,974 ± 250 1,840 ± 201(n=30) 1,820 ± 165 1,839 ± 241 1,781 ± 231(n=29) 1,703 ± 227(n=30) −8.7 (−11.0,  
−6.5)
0.20 <0.0001 −−2.8 (−4.0,  
−1.7)
0.83 <0.0001
spine
aBMD  
(g/cm2)
1.1 ± 0.1(n=27) 1.0 ± 0.1 0.9 ± 0.2 0.8 ± 0.1(n=30) 0.8 ± 0.1 0.8 ± 0.2(n=32) 0.8 ± 0.1(n=29) 0.7 ± 0.1(n=31) −0.008 (−0.01, 
−0.007)
0.34 <0.0001 −0.006  
(−0.008,  
−0.005)
0.50 <0.0001
BMC  
(g)
53.3 ± 9.5(n=27) 48.7 ± 10.1 45.5 ± 10.1 37.6 ± 8.1(n=30) 38.2 ± 7.2 37.6 ± 10.2(n=32) 35.7 ± 9.2(n=29) 32.9 ± 8.5(n=31) −0.5 (−0.6,  
−0.4)
0.29 <0.0001 −0.3 (−0.4,  
−0.2)
0.58 <0.0001
BA  
(cm2)
48.6 ± 3.6(n=27) 48.5 ± 4.9 48.5 ± 4.4 46.4 ± 5.4(n=30) 46.9 ± 4.3 47.7 ± 5.2(n=32) 45.6 ± 5.1(n=29) 44.9 ± 6.1(n=31) −0.1 (−0.2,  
−0.1)
0.07 <0.0001 −0.007  
(−0.05,  
0.03)
0.47 0.734
Total hip
aBMD  
(g/cm2)
1.0 ± 0.2(n=27) 1.0 ± 0.1(n=30) 0.9 ± 0.1 0.8 ± 0.1(n=30) 0.8 ± 0.1(n=29) 0.7 ± 0.1(n=32) 0.7 ± 0.1(n=29) 0.7 ± 0.1(n=33) −0.009 (−0.01, 
−0.008)
0.44 <0.0001 −0.008  
(−0.009,  
−0.006)
0.51 <0.0001
BMC  
(g)
28.6 ± 5.0(n=27) 28.1 ± 4.8(n=30) 25.0 ± 4.5 23.0 ± 3.3(n=30) 22.0 ± 3.2(n=29) 21.9 ± 3.6(n=32) 20.9 ± 4.4(n=29) 19.2 ± 3.9(n=33) −0.2 (−0.3,  
−0.2)
0.35 <0.0001 −0.2 (−0.2,  
−0.1)
0.51 <0.0001
BA (cm2) 28.3 ± 2.1(n=27) 28.5 ± 1.9(n=30) 28.8 ± 2.1 28.3 ± 2.0(n=30) 28.5 ± 1.9(n=29) 29.6 ± 2.3(n=32) 28.4 ± 2.3(n=29) 28.6 ± 2.3(n=33) 0.004 (−0.02,  
0.03)
0.0005 0.719 0.04 (0.02,  
0.06)
0.39 <0.0001
Femoral neck
aBMD  
(g/cm2)
1.0 ± 0.1(n=27) 1.0 ± 0.1(n=30) 0.9 ± 0.1 0.8 ± 0.1(n=30) 0.8 ± 0.1(n=29) 0.7 ± 0.1(n=32) 0.7 ± 0.1(n=29) 0.7 ± 0.1(n=32) −0.008 (−0.01, 
−0.007)
0.45 <0.0001 −0.007  
(−0.008,  
−0.006)
0.54 <0.0001
BMC  
(g)
4.1 ± 0.8(n=27) 4.0 ± 0.8(n=30) 3.6 ± 0.8 3.3 ± 0.7(n=30) 3.2 ± 0.6(n=29) 3.1 ± 0.7(n=32) 3.0 ± 0.7(n=29) 2.6 ± 0.7(n=32) −0.04 (−0.04,  
−0.03)
0.29 <0.0001 −0.03  
(−0.03,  
−0.02)
0.44 <0.0001
BA  
(cm2)
4.2 ± 0.7(n=27) 4.1 ± 0.6(n=30) 4.2 ± 0.6 4.1 ± 0.7(n=30) 4.1 ± 0.6(n=29) 4.2 ± 0.7(n=32) 4.2 ± 0.6(n=29) 3.9 ± 0.7(n=32) −0.005 (−0.01,  
0.002)
0.01 0.124 0.001  
(−0.006,  
0.008)
0.14 0.775
radius
aBMD  
(g/cm2)
0.6 ± 0.1(n=27) 0.6 ± 0.1 0.6 ± 0.1 0.5 ± 0.1(n=29) 0.5 ± 0.1 0.4 ± 0.1 0.5 ± 0.1 0.4 ± 0.1(n=32) −0.006 (−0.007, 
−0.005)
0.44 <0.0001 −0.005  
(−0.005,  
−0.004)
0.58 <0.0001
BMC  
(g)
9.0 ± 1.5(n=27) 8.8 ± 1.2 8.3 ± 1.8 7.0 ± 1.2(n=29) 7.1 ± 1.3 6.8 ± 1.6 6.6 ± 1.4 6.1 ± 1.2(n=32) −0.08 (−0.09,  
−0.06)
0.31 <0.0001 −0.05 (−0.06, 
−0.04)
0.60 <0.0001
BA  
(cm2)
14.5 ± 1.3(n=27) 15.0 ± 1.7 14.7 ± 1.8 14.8 ± 1.5(n=29) 15.0 ± 1.6 15.6 ± 1.2 14.7 ± 1.5 15.3 ± 1.9(n=32) 0.01 (−0.003,  
0.03)
0.01 0.103 0.04 (0.03,  
0.05)
0.41 <0.0001
Values are mean ± SD.
Bold indicates significance.
Adjustments were made for weight and height.
β-Coefficients are calculated with age as a continuous variable.
Superscript values indicate the group numbers.
aBMD, areal bone mineral density; BMC, bone mineral content; BA, bone area.
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FigUre 4 | Associations between age and clinically relevant bone outcomes (a) L1–L4 areal bone mineral density (aBMD), (B) total hip aBMD, (c) femoral neck 
aBMD, (D) 4% radius total volumetric BMD, (e) 33% radius cortical thickness, and (F) 33% radius cross-sectional area. Scatter plots are from linear regression with 
adjustments for sex, weight, and height. Blue lines and dots represent men and red lines and dots represent women.
Data from pQCT in men and women are shown in Tables 7 and 8, 
respectively. At the distal radius, there were greater negative dif-
ferences with age in women compared to men in the 4% total 
vBMD. At the 33% cortical site, there was a greater reduction 
in cortical thickness in women than in men and a concurrent 
greater decrease in cortical vBMD. There were small, but greater 
increases in CSA in women (Figures  4D–F). At the 4% tibia, 
there were greater negative differences in Trab.vBMD with age 
in women than in men following adjustments for body size 
(R2 = 0.41, interaction p < 0.0001).
From the LVA scans, 9% of GamBAS participants had moderate 
or severe vertebral fractures (as defined by GE Lunar software), 
and 14% had spinal degeneration (osteophytes present). Hip frac-
tures were self-reported; 3% of women and 0.4% of men reported 
a hip fracture, or fracture-like injury. Comparing the GamBAS 
participants to the manufacturers US Black reference database 
showed the population to have lower age, and gender-matched 
Z-scores for aBMD than the reference for both the lumbar spine 
and hip. The mean (SD), range of those Z-scores are: lumbar spine 
L1–L4, women −2.0 (1.1), −4.7 to 1.5; men −1.5 (1.3), −4.4 to 
3.9 and for femoral neck, women −1.1 (0.9), −3.3 to 2.0; men 
−1.0 (0.9), −3.2 to 1.7. Peripheral vascular calcification in the 
lower-limb was visible in 16% of the population. There were no 
sex differences in the presence of peripheral vascular calcifica-
tion: 19% in men vs 15% in women, p = 0.195.
DiscUssiOn
GamBAS is the first and largest prospective longitudinal study 
in West Africa in which quantitative measurements of bone and 
muscle have been collected. The initial findings have highlighted 
that women have a greater degree of aBMD loss compared to 
men, yet have less loss of muscle. Analyses of longitudinal data 
will allow more accurate quantification of this loss and investiga-
tion of the mechanisms driving these effects. Data from DXA 
demonstrate that height-adjusted BA increased with age at the 
total hip and radius in both men and women; however, pQCT 
revealed that the increase in cross-sectional BA at the radius 
was only evident in women. The decrease in cortical thickness 
in women suggests this increase in cross-sectional BA may be a 
biomechanical adaptation to loss of bone. However, whether this 
is indicative of a cohort effect or age-related periosteal apposition 
will be confirmed in analysis of prospective data. In agreement 
with our previous work, the magnitude of age-differences is 
similar to that observed in other populations, where fracture 
incidence is higher.
Our preliminary analyses of cross-sectional data show that 
total hip aBMD was negatively associated with age in Gambian 
men and women. Self-reported hip fracture rates were 0.4–3% and 
lower compared to sex- and age-adjusted hip fracture incidence 
elsewhere in the world (32). The aBMD Z-scores we report show 
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TaBle 7 | Peripheral quantitative computed tomography bone parameters in men.
age (yr) 40–44  
(n = 25)
45–49  
(n = 34)
50–54  
(n = 29)
55–59  
(n = 31)
60–64  
(n = 27)
65–69  
(n = 35)
70–74  
(n = 30)
75+  
(n = 28)
β-coefficient 
(95% ci)
R2 Unadjusted 
p-value
β-coefficient 
(95% ci)
R2 adjusted 
p-value
radius
4% Total vBMD 
(mg/cm3)
362.5 ± 45.1(n=22) 327.3 ± 39.6(n=27) 327.0 ± 45.0(n=25) 331.9 ± 56.2(n=26) 296.2 ± 52.5(n=24) 292.6 ± 55.8(n=25) 276.0 ± 46.2(n=25) 292.2 ± 57.5(n=23) −1.92 (−2.5, −1.3) 0.18 <0.0001 −1.77 (−2.4, −1.2) 0.20 <0.0001
4% Trab.vBMD 
(mg/cm3)
206.5 ± 44.7(n=22) 181.6 ± 39.7(n=27) 173.1 ± 31.3(n=25) 177.3 ± 41.8(n=26) 152.3 ± 40.2(n=24) 147.9 ± 38.6(n=25) 149.6 ± 34.6(n=25) 140.2 ± 35.2(n=23) −1.57 (−2.0, −1.1) 0.21 <0.0001 −1.45 (−1.9, −1.0) 0.23 <0.0001
33% Ct.vBMD 
(mg/cm3)
1,228.9 ± 35.8(n=24) 1,230.8 ± 37.8(n=29) 1,235.0 ± 33.8(n=25) 1,224.0 ± 34.1(n=28) 1,203.2 ± 44.9(n=23) 1,203.8 ± 25.9(n=26) 1,192.5 ± 30.1(n=25) 1,207.0 ± 31.4(n=23) −0.96 (−1.4, −0.6) 0.10 <0.0001 −0.94 (−1.4, −0.5) 0.11 <0.0001
33% CSA (mm2) 139.5 ± 18.0(n=24) 135.2 ± 20.2(n=29) 142.8 ± 20.0(n=25) 140.9 ± 16.5(n=28) 142.6 ± 17.4(n=23) 134.7 ± 19.3(n=26) 138.8 ± 20.4(n=25) 133.4 ± 14.9(n=23) −0.12 (−0.3, 0.1) 0.01 0.274 0.14 (−0.1, 0.3) 0.19 0.188
33% Ct.Th (mm) 2.7 ± 0.3(n=24) 2.7 ± 0.3(n=29) 2.8 ± 0.3(n=25) 2.7 ± 0.3(n=28) 2.6 ± 0.3(n=23) 2.6 ± 0.4(n=26) 2.4 ± 0.4(n=25) 2.5 ± 0.3(n=23) −0.01 (−0.01, −0.01) 0.11 <0.0001 −0.01 (−0.01, −0.003) 0.16 0.001
33% SSI (mm3) 310.1 ± 0.3(n=24) 293.5 ± 63.0(n=29) 354.2 ± 80.3(n=25) 305.3 ± 69.8 (n=28) 332.6 ± 61.7(n=23) 297.9 ± 84.6(n=26) 309.2 ± 86.0(n=25) 287.9 ± 51.5(n=23) −0.60 (−1.4, 0.2) 0.01 0.150 0.32 (−0.5, 1.1) 0.17 <0.0001
Tibia
4% Total vBMD 
(mg/cm3)
316.9 ± 43.7 283.0 ± 38.3(n=30) 285.2 ± 39.2(n=25) 275.8 ± 37.1(n=28) 255.1 ± 42.5(n=25) 259.8 ± 48.3(n=32) 245.5 ± 33.0(n=27) 249.9 ± 40.1(n=24) −1.62 (−2.1, −1.2) 0.19 <0.0001 −1.45 (−1.9, −1.0) 0.31 <0.0001
4% Trab.vBMD 
(mg/cm3)
204.4 ± 40.3(n=24) 186.8 ± 33.9(n=30) 181.6 ± 29.3(n=25) 172.8 ± 26.9(n=28) 169.5 ± 32.2(n=25) 170.0 ± 37.0(n=32) 161.2 ± 25.6(n=27) 163.0 ± 30.0(n=24) −0.96 (−1.3, −0.6) 0.12 <0.0001 −0.81 (−1.2, −0.5) 0.25 <0.0001
38% Ct.vBMD 
(mg/cm3)
1,219.8 ± 33.8 1,218.6 ± 29.0(n=31) 1,220.1 ± 37.1(n=25) 1,218.7 ± 39.6(n=28) 1,199.5 ± 42.6(n=26) 1,204.3 ± 31.0(n=32) 1,193.6 ± 35.5(n=27) 1,202.4 ± 32.1(n=24) −0.62 (−1.0, −0.2) 0.05 0.002 −0.79 (−1.2, −0.4) 0.08 <0.0001
38% CSA (mm2) 472.2 ± 61.4 461.5 ± 64.3(n=31) 453.3 ± 52.2(n=25) 455.4 ± 39.1(n=28) 462.9 ± 66.6(n=26) 442.3 ± 55.1(n=32) 452.5 ± 63.4(n=27) 425.4 ± 38.8(n=24) −0.87 (−1.5, −0.3) 0.04 0.005 0.004 (−0.6, 0.6) 0.28 0.989
38% Ct.Th (mm) 5.0 ± 0.5 5.0 ± 0.5(n=31) 5.0 ± 0.4(n=25) 4.9 ± 0.5(n=28) 4.6 ± 0.6(n=26) 4.7 ± 0.6(n=32) 4.8 ± 0.7(n=27) 4.8 ± 0.6(n=24) −0.01 (−0.01, −0.001) 0.02 0.026 −0.004 (−0.01, 0.002) 0.07 0.203
38% SSI (mm3) 2,129.2 ± 360.9 2,043.5 ± 364.8(n=31) 2,033.3 ± 320.1(n=25) 2,046.3 ± 253.2(n=28) 1,928.8 ± 379.0(n=26) 1,896.7 ± 314.8(n=32) 1,949.7 ± 354.9(n=27) 1,839.5 ± 212.5(n=24) −6.37 (−9.9, −2.9) 0.06 <0.0001 −1.54 (−4.9, 1.8) 0.27 0.362
Values are mean ± SD.  
Bold indicates significance.  
Adjustments were made for weight and height. 
 β-Coefficients are calculated with age as a continuous variable.  
Superscript values indicate the group numbers.  
vBMD, volumetric bone mineral density; Trab, trabecular; Ct, cortical; Th, thickness; CSA, cross-sectional area; SSI, stress strain index.
TaBle 8 | Peripheral quantitative computed tomography bone parameters in women.
age (yr) 40–44  
(n = 28)
45–49  
(n = 32)
50–54  
(n = 30)
55–59  
(n = 31)
60–64  
(n = 31)
65–69  
(n = 33)
70–74  
(n = 30)
75+  
(n = 34)
β-coefficient  
(95% ci)
R2 Unadjusted 
p-value
β-coefficient 
(95% ci)
R2 adjusted 
p-value
radius  
4% Total vBMD 
(mg/cm3)
305.9 ± 46.1(n=25) 294.0 ± 47.3(n=30) 267.7 ± 45.5(n=26) 245.0 ± 34.9(n=25) 244.9 ± 43.6(n=25) 214.7 ± 42.8(n=29) 236.0 ± 39.1(n=22) 208.1 ± 39.1(n=30) −2.57 (−3.0, −2.1) 0.36 <0.0001 −2.31 (−2.8, −1.8) 0.41 <0.0001
4% Trab.vBMD 
(mg/cm3)
146.5 ± 37.0(n=25) 144.5 ± 33.8(n=30) 122.3 ± 30.3(n=26) 114.4 ± 27.9(n=25) 106.5 ± 21.0(n=25) 97.8 ± 30.8(n=29) 104.0 ± 16.8(n=22) 83.9 ± 29.9(n=30) −1.63 (−1.9, −1.3) 0.33 <0.0001 −1.52 (−1.9, −1.2) 0.35 <0.0001
33% Ct.vBMD 
(mg/cm3)
1,252.2 ± 39.8(n=26) 1,235.8 ± 46.4(n=29) 1,208.3 ± 52.8(n=28) 1,169.4 ± 46.6(n=27) 1,150.3 ± 35.7(n=25) 1,142.9 ± 52.5(n=28) 1,154.0 ± 37.5(n=22) 1,131.5 ± 45.5(n=25) −3.28 (−3.8, −2.7) 0.42 <0.0001 −3.03 (−3.6, −2.5) 0.45 <0.0001
33% CSA (mm2) 104.8 ± 11.9(n=26) 109.0 ± 11.7(n=29) 108.8 ± 16.6(n=28) 108.9 ± 17.1(n=27) 109.6 ± 11.7(n=25) 111.0 ± 11.7(n=28) 105.5 ± 13.0(n=22) 115.6 ± 16.7(n=25) 0.18 (0.02, 0.3) 0.02 0.027 0.33 (0.2, 0.5) 0.23 <0.0001
33% Ct.Th (mm) 2.4 ± 0.3(n=26) 2.3 ± 0.3(n=29) 2.2 ± 0.4(n=28) 1.8 ± 0.3(n=27) 1.8 ± 0.3(n=25) 1.7 ± 0.4(n=28) 1.7 ± 0.4(n=22) 1.5 ± 0.3(n=25) −0.02 (−0.03, −0.02) 0.43 <0.0001 −0.02 (−0.02, −0.02) 0.50 <0.0001
33% SSI (mm3) 215.5 ± 37.4(n=26) 222.7 ± 34.8(n=29) 211.6 ± 53.3(n=28) 189.0 ± 37.1(n=27) 194.4 ± 34.5(n=25) 193.7 ± 126.2(n=28) 185.8 ± 33.3(n=22) 191.0 ± 43.1(n=25) −0.89 (−1.3, −0.4) 0.07 <0.0001 −0.39 (−0.8, 0.01) 0.29 0.06
Tibia
4% Total vBMD 
(mg/cm3)
290.1 ± 36.0(n=26) 276.5 ± 38.9(n=30) 255.5 ± 36.8(n=30) 225.5 ± 29.4(n=28) 224.2 ± 30.4(n=27) 201.1 ± 35.5(n=31) 206.6 ± 38.2(n=25) 187.2 ± 36.7(n=31) −2.72 (−3.1, −2.3) 0.47 <0.0001 −2.5 (−2.9, −2.1) 0.55 <0.0001
4% Trab.vBMD 
(mg/cm3)
195.5 ± 28.6(n=26) 186.3 ± 33.6(n=30) 163.9 ± 32.0(n=30) 141.0 ± 32.1(n=28) 139.5 ± 25.5(n=27) 133.8 ± 34.0(n=31) 137.6 ± 30.9(n=25) 119.0 ± 31.6(n=31) −1.90 (−2.2, −1.57) 0.35 <0.0001 −1.65 (−2.0, −1.3) 0.43 <0.0001
38% Ct.vBMD 
(mg/cm3)
1,234.9 ± 43.4(n=26) 1,215.1 ± 49.9(n=30) 1,197.3 ± 46.2(n=30) 1,161.8 ± 44.8(n=28) 1,145.0 ± 49.0(n=27) 1,144.4 ± 53.8(n=31) 1,147.7 ± 47.0(n=25) 1,128.2 ± 55.3(n=31) −2.64 (−3.2, −2.1) 0.29 <0.0001 −2.45 (−3.0, −1.9) 0.31 <0.0001
38% CSA (mm2) 362.0 ± 49.7(n=26) 363.2 ± 43.1(n=30) 355.5 ± 48.5(n=30) 363.8 ± 43.5(n=28) 359.1 ± 35.7(n=27) 373.8 ± 56.5(n=31) 334.5 ± 46.4(n=25) 360.4 ± 52.7(n=31) −0.16 (−0.7, 0.3) 0.01 0.530 0.48 (−0.001, 1.0) 0.22 0.050
38% Ct.Th (mm) 4.1 ± 0.6(n=26) 4.0 ± 0.6(n=30) 3.9 ± 0.4(n=30) 3.7 ± 0.5(n=28) 3.5 ± 0.6(n=27) 3.6 ± 0.7(n=31) 3.3 ± 0.7(n=25) 3.0 ± 0.6(n=31) −0.03 (−0.03, −0.02) 0.23 <0.0001 −0.02 (−0.03, −0.01) 0.33 <0.0001
38% SSI (mm3) 1,430.8 ± 271.2(n=26) 1,359.2 ± 226.1(n=30) 1,353.3 ± 283.8(n=30) 1,350.1 ± 224.8(n=28) 1,244.8 ± 146.2(n=27) 1,338.9 ± 313.4(n=31) 1,134.5 ± 250.5(n=25) 1,175.1 ± 227.5(n=31) −6.34 (−9.0, −3.7) 0.09 <0.0001 −2.55 (−5.0, −0.1) 0.34 0.038
Values are mean ± SD.
Bold indicates significance.
Adjustments were made for weight and height.
β-Coefficients are calculated with age as a continuous variable.
Superscript values indicate the group numbers.
vBMD, volumetric bone mineral density; Trab, trabecular; Ct, cortical; Th, thickness; CSA, cross-sectional area; SSI, stress strain index.
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that Gambian men and women had osteoporosis at the lumbar 
spine compared to the manufacturer’s reference US Black popula-
tion. However, this population may not be the most appropriate 
one to use as a reference and may have led to overestimating the 
prevalence of osteoporosis in the population (33, 34). Using the 
LVA scans, for the first time we report the prevalence of vertebral 
fractures in this cohort as 9%, with 6% in men and 3% in women. 
The prevalence of vertebral fractures among GamBAS participants 
is consistent with a recent report in South African women, where 
prevalence was 9 and 5% in black and white women, respectively 
(35). The positive association between spine BA and age in men 
may be due to spinal degeneration artefact and requires further 
investigation.
Calcium is one of the main mineral components of the skeletal 
system, and adequate dietary intake is essential for healthy bones. 
In adults from high-income countries, low calcium intake has 
been associated with an increased risk of osteoporosis, fractures, 
and falls (36). We report that habitual dietary calcium intake across 
the age bands in Gambian adults was low relative to international 
recommendations, for example in the UK the reference nutrient 
intake for adults is 700 mg/day (37) and in the US and Canada 
1,000–1,200 mg/d (38). Furthermore, dietary calcium intake was 
low in Gambians compared to UK adults (743–912 mg/day) (39) 
and American adults (748–1,209 mg/day) (40). Future analyses 
of longitudinal data investigating the relationship between 
dietary intake and musculoskeletal health in Gambian men and 
women are therefore warranted. It is important to note that in our 
groups other work in children and women of reproductive age, 
increasing calcium intake did not have a lasting benefit, and find-
ings contradict those that we would expect in countries where 
habitual intakes are much higher (18, 41–45).
The strengths and potential limitations of GamBAS merit 
consideration. This was the first study of ageing in The Gambia 
and we did not know how well the study would be accepted by 
the older community in Kiang West. We achieved our sample 
target within each of our age-stratified groups; the stratified study 
design ensured equal distribution of sampling across the age 
bands of men and women recruited. Our suite of measurements 
is unique and allows detailed characterisation of musculoskeletal 
outcomes. The long-standing relationship between the popula-
tion of Kiang West and MRC Keneba is maintained through 
high levels of communication and interaction with a “research-
friendly” population. The KWDSS information dates back to the 
1950’s so that accurate dates of birth for determination of age in 
the older-age bands is possible and also facilitated study design 
and recruitment stratification by age and village.
We could not accurately assess menopausal status from the 
women’s health questionnaire as some questions did not trans-
late well in the local language leading to errors in information. 
Fertility status is sensitive in The Gambian culture and so future 
studies investigating how best to determine menopausal status 
are required. It was not possible to distinguish secular differences 
in attained adult size (older men and women were born at a 
time when early growth faltering may have been more severe) 
from age-related changes from the reported cross-sectional 
data. However, this will be possible with the longitudinal data. 
The majority of recruits were from the four core villages which 
may be healthier than the other villages as they are located closer 
to MRC Keneba where the residents are able to receive medical 
care. This, and that we only needed to recruit 30% of the Kiang 
West residents, to achieve our target sample size, may cause bias 
in our findings. In The Gambia, traditional bone-setters tend to 
be used for the treatment of musculoskeletal disorders, includ-
ing fractures, and the information is not added to clinic medical 
records. Therefore, the hip fracture data obtained are based on 
self-report and may be inaccurate or incomplete because verifi-
cation through radiograph reports is not possible. The vertebral 
fracture data are from GE Lunar Prodigy scans; in later follow-up 
using the higher-resolution iDXA, we will be able to more accu-
rately assess vertebral fractures. There was difficulty in obtaining 
medical records from the participants who were not living in the 
four core villages of Kiang West. This is a homogenous population 
with little variance in lifestyle characteristics. When comparing 
to other regions, sub-Saharan Africa or the globe, it will be 
important to investigate further the effects of environment such 
as physical activity levels and occupation. Finally, Kiang West is 
one region of The Gambia and the data may not be generalizable 
to urban areas of the country, to other West African countries or 
to the remainder of the continent.
In conclusion, the GamBAS cohort provides important infor-
mation on the aetiology of ageing in a rural sub-Saharan setting. 
This is crucial as the ageing population increases and with it, 
NCD burden.
cOllaBOraTiOn
The MRC has a long and successful history of conducting col-
laborative research and we welcome specific proposals for new 
collaborations. Data sharing is available through collaborative 
agreements and initial enquiries should be made to the Principal 
Investigator Kate Ward (kw@mrc.soton.ac.uk).
eThics sTaTeMenT
Ethics was obtained from the MRC Unit The Gambia Scientific 
Co-ordinating Committee (SCC) and joint Gambian Government/ 
MRC Unit The Gambia Ethics committee (SCC#1222). All par-
ticipants provided written informed consent. All procedures 
were carried out in accordance with the Declaration of Helsinki 
(28). If any participant had potential health problems identified 
by fieldworkers during recruitment or by the team during the 
field visit, they were advised to visit the clinic at MRC Keneba for 
follow-up and were offered transport. Participants with elevated 
blood pressure [according to WHO guidelines (29)] were fol-
lowed up and treated as appropriate. Any other abnormalities 
were discussed with the study physician who followed-up appro-
priately. For instance, if musculoskeletal abnormalities were 
detected on the scan, the participant was referred for radiography 
at MRC Fajara.
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